KIP Medical is focused on research and development of an innovative plant-derived solution to treat patients with various pathological conditions involving dysregulation of the immune system, such as autoimmune diseases and transplanted organ rejection, increased activity of the immune system caused by inflammation and tissue damage, and more. KIP Medical is uniquely positioned to address the unmet medical needs of enhancing the control of the immune system in pathological immune disorders. Currently, it is focused specifically on developing a novel drug that promises to innovate the therapy of dry mouth syndrome and other inflammatory conditions. KIP Medical was born out of the collaboration between Hadassah Medical Center, Prof. Reuven Or, Dr. Osnat Hazan and Pollen Innovation Ltd, an Israeli-based investment firm focused on accelerating disruptive innovations and trends that enhance quality of life and contribute to a better and healthier world.